For example, if the therapeutically targetable IDH1/2 mutations are detected during the chronic or accelerated/blast phase MPN, treatment with IDH1 (ivosidenib, olutasidenib) or IDH2 (enasidenib) inhibitors alone or in combination with JAK inhibitors or hypomethylating agents may be considered [83,84,85]. Here, IDH1 is linked to myeloproliferative disorder.